$RBOT News

Vicarious Surgical Demonstrates Sustained System Performance and Complex Hernia Procedure Workflows in Pre-Clinical Setting

Vicarious Surgical Reports First Quarter 2026 Financial Results

CORRECTION: Vicarious Surgical Q1 EPS $(1.03) Beats $(1.08) Estimate

Vicarious Surgical Completes Integrated Benchtop Testing of Full Surgical Instrument Suite for Ventral Hernia Repair

Vicarious Surgical Begins Quotation on the OTCQB as Part of Strategic Path Toward Potential Nasdaq Listing

Vicarious Surgical Announces Strategic Plan to Pursue Nasdaq Listing

Vicarious Surgical Reports Fourth Quarter and Full Year 2025 Financial Results

Vicarious Surgical Q4 Adj. EPS $(1.65) Misses $(1.37) Estimate

Vicarious Surgical receives NYSE delisting notice

Vicarious Surgical Receives Delisting Notice From NYSE

Vicarious Surgical Receives NYSE Delisting Notice After Falling Below $15M Market Cap Requirement, Stock To Begin Trading On OTCID Market March 4

Vicarious Surgical Receives NYSE Delisting Notice After Falling Below $15M Market Cap Requirement, Stock To Begin Trading On OTCID Market March 4

NYSE to Commence Delisting Proceedings Against Vicarious Surgical Inc. (RBOT)

Vicarious Surgical Advances Toward Design Freeze with Successful In-Vivo Porcine Lab

Vicarious Surgical Successfully Completes In-Vivo Porcine Lab, Advancing Robotic Surgery System Development Toward 2026 Design Freeze

Vicarious inks software partnership as it streamlines operations

RBOT Enters Strategic Software Partnership to Streamline Development

Vicarious Surgical Announces Strategic Software Execution Partnership to Streamline Operations

Vicarious Surgical (RBOT) Price Target Decreased by 44.44% to 5.10

NYSE to Commence Delisting Proceedings with Respect to Warrants of Vicarious Surgical Inc. (RBOT WS)